Omeros (OMER) to Release Earnings on Monday

Omeros (NASDAQ:OMER - Get Free Report) is projected to release its earnings data after the market closes on Monday, March 24th. Analysts expect Omeros to post earnings of ($0.69) per share for the quarter.

Omeros Stock Down 0.9 %

Shares of NASDAQ:OMER traded down $0.08 during midday trading on Monday, reaching $9.02. The company's stock had a trading volume of 348,909 shares, compared to its average volume of 530,017. The firm has a 50 day moving average of $8.71 and a 200-day moving average of $7.40. The firm has a market capitalization of $522.71 million, a P/E ratio of -3.90 and a beta of 2.03. Omeros has a 12-month low of $2.61 and a 12-month high of $13.60.

Wall Street Analyst Weigh In

Several analysts recently weighed in on OMER shares. D. Boral Capital restated a "buy" rating and issued a $36.00 price target on shares of Omeros in a research note on Friday. StockNews.com cut Omeros from a "hold" rating to a "sell" rating in a research report on Friday. Finally, Needham & Company LLC reissued a "hold" rating on shares of Omeros in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $22.50.

Remove Ads

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.